Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H26ClN3O |
Molecular Weight | 335.872 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CCO)CCCC(C)NC1=CC=NC2=C1C=CC(Cl)=C2
InChI
InChIKey=XXSMGPRMXLTPCZ-UHFFFAOYSA-N
InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
DescriptionSources: http://www.drugbank.ca/drugs/DB01611Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB01611
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf
Hydroxychloroquine possesses antimalarial properties and also exerts a beneficial effect in lupus erythematosus (chronic discoid or systemic) and acute or chronic rheumatoid arthritis. Although the exact mechanism of action is unknown, it may be based on ability of hydroxychloroquine to bind to and alter DNA. Hydroxychloroquine has also has been found to be taken up into the acidic food vacuoles of the parasite in the erythrocyte. This increases the pH of the acid vesicles, interfering with vesicle functions and possibly inhibiting phospholipid metabolism. In suppressive treatment, hydroxychloroquine inhibits the erythrocytic stage of development of plasmodia. In acute attacks of malaria, it interrupts erythrocytic schizogony of the parasite. Its ability to concentrate in parasitized erythrocytes may account for their selective toxicity against the erythrocytic stages of plasmodial infection. As an antirheumatic, hydroxychloroquine is thought to act as a mild immunosuppressant, inhibiting the production of rheumatoid factor and acute phase reactants. It also accumulates in white blood cells, stabilizing lysosomal membranes and inhibiting the activity of many enzymes, including collagenase and the proteases that cause cartilage breakdown. Hydroxychloroquine is used for the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5936 Sources: http://www.drugbank.ca/drugs/DB01611 |
2.78 µM [IC50] | ||
Target ID: CHEMBL5804 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24342772 |
0.08 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | PLAQUENIL Approved UsePLAQUENIL is indicated for the suppressive treatment and treatment of acute attacks of
malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum.
It is also indicated for the treatment of discoid and systemic lupus erythematosus, and
rheumatoid arthritis. Launch Date-4.64227205E11 |
|||
Primary | PLAQUENIL Approved UsePLAQUENIL is indicated for the suppressive treatment and treatment of acute attacks of
malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum.
It is also indicated for the treatment of discoid and systemic lupus erythematosus, and
rheumatoid arthritis. Launch Date-4.64227205E11 |
|||
Primary | PLAQUENIL Approved UsePLAQUENIL is indicated for the suppressive treatment and treatment of acute attacks of
malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum.
It is also indicated for the treatment of discoid and systemic lupus erythematosus, and
rheumatoid arthritis. Launch Date-4.64227205E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
129.6 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYCHLOROQUINE SULFATE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.22 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19188392 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYCHLOROQUINE SULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
50.3 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYCHLOROQUINE SULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
102.3 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19188392 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYCHLOROQUINE SULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
537 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYCHLOROQUINE SULFATE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
172.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19188392 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYCHLOROQUINE SULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2963 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYCHLOROQUINE SULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
48% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8359187 |
unknown, unknown |
HYDROXYCHLOROQUINE SULFATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
12 g 1 times / day single, oral Studied dose Dose: 12 g, 1 times / day Route: oral Route: single Dose: 12 g, 1 times / day Sources: |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: M Population Size: 1 Sources: |
Other AEs: Cardio-respiratory arrest... |
200 mg 1 times / day single, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: single Dose: 200 mg, 1 times / day Co-administed with:: levothyroxine Sources: aspirin ibuprofen |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: F Population Size: 1 Sources: |
Other AEs: Tachycardia, Hypotension... Other AEs: Tachycardia Sources: Hypotension Depression Hypokalemia |
20 g 1 times / day single, oral Studied dose Dose: 20 g, 1 times / day Route: oral Route: single Dose: 20 g, 1 times / day Sources: |
healthy, 18 years n = 1 Health Status: healthy Age Group: 18 years Sex: F Population Size: 1 Sources: |
Other AEs: Hypotension, Hypokalemia... |
12 g 1 times / day single, oral Studied dose Dose: 12 g, 1 times / day Route: oral Route: single Dose: 12 g, 1 times / day Sources: |
healthy, 2.5 years n = 1 Health Status: healthy Age Group: 2.5 years Sex: M Population Size: 1 Sources: |
Other AEs: Cardio-respiratory arrest... |
4 g 1 times / day single, oral Studied dose Dose: 4 g, 1 times / day Route: oral Route: single Dose: 4 g, 1 times / day Sources: |
healthy, 29 years n = 1 Health Status: healthy Age Group: 29 years Sex: M Population Size: 1 Sources: |
Other AEs: Vomiting, Ventricular tachycardia... |
600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
DLT: Nausea, Vomiting... Other AEs: Lymphopenia, Anemia... Dose limiting toxicities: Nausea (grade 3, 13%) Other AEs:Vomiting (grade 3, 13%) Lymphopenia (grade 3-4, 13%) Sources: Anemia (grade 1-2, 13%) Thrombocytopenia (grade 1-2, 13%) Anorexia (grade 1-2, 38%) Bradycardia (grade 1-2, 13%) Constipation (grade 1-2, 25%) Diarrhea (grade 1-2, 25%) Fatigue (grade 1-2, 88%) Hypotension (grade 1-2, 13%) Nausea (grade 1-2, 50%) Rash (grade 1-2, 13%) Vomiting (grade 1-2, 25%) |
200 mg 2 times / day multiple, oral Studied dose Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 15 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 15 Sources: |
DLT: Heart block... Dose limiting toxicities: Heart block (grade 3, 6.7%) Sources: |
500 mg 2 times / day multiple, oral Studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 7 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 7 Sources: |
DLT: Rash... |
200 mg 2 times / day steady, oral Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy n = 7 Health Status: unhealthy Condition: cardiovascular disease Population Size: 7 Sources: |
Other AEs: Increased blood pressure... Other AEs: Increased blood pressure (below serious, 1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cardio-respiratory arrest | grade 5 | 12 g 1 times / day single, oral Studied dose Dose: 12 g, 1 times / day Route: oral Route: single Dose: 12 g, 1 times / day Sources: |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: M Population Size: 1 Sources: |
Depression | 200 mg 1 times / day single, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: single Dose: 200 mg, 1 times / day Co-administed with:: levothyroxine Sources: aspirin ibuprofen |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: F Population Size: 1 Sources: |
|
Hypokalemia | 200 mg 1 times / day single, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: single Dose: 200 mg, 1 times / day Co-administed with:: levothyroxine Sources: aspirin ibuprofen |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: F Population Size: 1 Sources: |
|
Hypotension | 200 mg 1 times / day single, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: single Dose: 200 mg, 1 times / day Co-administed with:: levothyroxine Sources: aspirin ibuprofen |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: F Population Size: 1 Sources: |
|
Tachycardia | 200 mg 1 times / day single, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: single Dose: 200 mg, 1 times / day Co-administed with:: levothyroxine Sources: aspirin ibuprofen |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: F Population Size: 1 Sources: |
|
Hypokalemia | 20 g 1 times / day single, oral Studied dose Dose: 20 g, 1 times / day Route: oral Route: single Dose: 20 g, 1 times / day Sources: |
healthy, 18 years n = 1 Health Status: healthy Age Group: 18 years Sex: F Population Size: 1 Sources: |
|
Hypotension | 20 g 1 times / day single, oral Studied dose Dose: 20 g, 1 times / day Route: oral Route: single Dose: 20 g, 1 times / day Sources: |
healthy, 18 years n = 1 Health Status: healthy Age Group: 18 years Sex: F Population Size: 1 Sources: |
|
Cardio-respiratory arrest | grade 5 | 12 g 1 times / day single, oral Studied dose Dose: 12 g, 1 times / day Route: oral Route: single Dose: 12 g, 1 times / day Sources: |
healthy, 2.5 years n = 1 Health Status: healthy Age Group: 2.5 years Sex: M Population Size: 1 Sources: |
Ventricular tachycardia | 4 g 1 times / day single, oral Studied dose Dose: 4 g, 1 times / day Route: oral Route: single Dose: 4 g, 1 times / day Sources: |
healthy, 29 years n = 1 Health Status: healthy Age Group: 29 years Sex: M Population Size: 1 Sources: |
|
Vomiting | 4 g 1 times / day single, oral Studied dose Dose: 4 g, 1 times / day Route: oral Route: single Dose: 4 g, 1 times / day Sources: |
healthy, 29 years n = 1 Health Status: healthy Age Group: 29 years Sex: M Population Size: 1 Sources: |
|
Anemia | grade 1-2, 13% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Bradycardia | grade 1-2, 13% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Hypotension | grade 1-2, 13% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Rash | grade 1-2, 13% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Thrombocytopenia | grade 1-2, 13% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Constipation | grade 1-2, 25% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Diarrhea | grade 1-2, 25% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Vomiting | grade 1-2, 25% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Anorexia | grade 1-2, 38% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Nausea | grade 1-2, 50% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Fatigue | grade 1-2, 88% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Nausea | grade 3, 13% DLT |
600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Vomiting | grade 3, 13% DLT |
600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Lymphopenia | grade 3-4, 13% | 600 mg 2 times / day multiple, oral Highest studied dose Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 8 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 8 Sources: |
Heart block | grade 3, 6.7% DLT |
200 mg 2 times / day multiple, oral Studied dose Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 15 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 15 Sources: |
Rash | grade 3, 14.3% DLT |
500 mg 2 times / day multiple, oral Studied dose Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Co-administed with:: temozolomide(150 mg/m2; daily for 7/14 d) Sources: |
unhealthy, median age 64 years n = 7 Health Status: unhealthy Condition: advanced solid malignancies Age Group: median age 64 years Sex: M+F Population Size: 7 Sources: |
Increased blood pressure | below serious, 1 patient | 200 mg 2 times / day steady, oral Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: |
unhealthy n = 7 Health Status: unhealthy Condition: cardiovascular disease Population Size: 7 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | yes (co-administration study) Comment: Concomitant administration of HCQ increased the bioavailability of metoprolol, as indicated by significant increases in the area under the plasma concentration-time curve (65 ± 4.6%) and maximal plasma concentrations (72 ± 6.9%) of metoprolol |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
likely | ||||
likely |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Discontinuation of antimalarial drugs in systemic lupus erythematosus. | 1999 Apr |
|
November 1998--70 year old woman with SLE, paraproteinemia and polyneuropathy. | 1999 Apr |
|
[Complications of colonic diverticular disease during rheumatoid polyarthritis: 7 cases]. | 1999 Jan |
|
Hydroxychloroquine ototoxicity in a patient with rheumatoid arthritis. | 2000 |
|
Hydroxychloroquine neuromyotoxicity. | 2000 Dec |
|
Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis. | 2001 |
|
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. | 2001 |
|
Treatment of systemic lupus erythematosus with bromocriptine. | 2001 |
|
Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients. | 2001 Apr |
|
Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. | 2001 Aug 11 |
|
[Combined basic therapeutic drugs. From individual hope to targeted use]. | 2001 Dec |
|
Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. | 2001 Jan |
|
Hydroxychloroquine enhances the endocrine secretion of adenovirus-directed growth hormone from rat submandibular glands in vivo. | 2001 Jul 1 |
|
Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? | 2001 Jun |
|
[Photodermatosis induced by hydroxychloroquine: 4 cases]. | 2001 Jun-Jul |
|
[Subacute cutaneous lupus gyratus repens]. | 2001 Mar |
|
Reversible blindness resulting from optic chiasmitis secondary to systemic lupus erythematosus. | 2001 Mar |
|
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. | 2001 Sep 8 |
|
Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. | 2002 Apr |
|
Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. | 2002 Feb |
|
Hydroxychloroquine ototoxicity in a child with idiopathic pulmonary haemosiderosis. | 2002 Jan 11 |
|
Nonendemic pemphigus foliaceus in children. | 2002 Mar |
Patents
Sample Use Guides
Malaria: Suppression— In adults, 400 mg (=310 mg base) on exactly the same day of each week. In infants and children, the weekly suppressive dosage is 5 mg, calculated as base, per kg of body weight, but should not exceed the adult dose regardless of weight.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23778483
After 48 hours of stimulation with PMA and ionomycin, Hydroxychloroquine (25-100 uM) inhibited the production of IL-6, IL-17 and IL-22 in the PBMCs of healthy volunteers
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/16/1820
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
2.4
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
||
|
NCI_THESAURUS |
C271
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
||
|
WHO-ATC |
P01BA02
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
||
|
LIVERTOX |
NBK548738
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
||
|
NDF-RT |
N0000175482
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
||
|
NDF-RT |
N0000175713
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1395
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
100000083659
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
m6127
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | Merck Index | ||
|
4QWG6N8QKH
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
5801
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
HYDROXYCHLOROQUINE
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
SUB08077MIG
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
7198
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
5521
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | RxNorm | ||
|
4QWG6N8QKH
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
DTXSID8023135
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
D006886
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
DB01611
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
C557
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
3652
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
CHEMBL1535
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
204-249-8
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
118-42-3
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
Hydroxychloroquine
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY | |||
|
796
Created by
admin on Sat Dec 16 17:54:56 UTC 2023 , Edited by admin on Sat Dec 16 17:54:56 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE ACTIVE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE ACTIVE (PARENT)